PARIS--(BUSINESS WIRE)--
Regulatory News:
Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.
Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.
The company will attend the following events:
European Academy of Neurology (EAN) congress
June 16-18,
2018 in Lisbon, Portugal
Two ePosters (oral communications)
| #EPR1170 |
A multicenter, double-blind, placebo-controlled, pivotal phase
III study (PLEO-CMT) of a |
|
| Presenter: | Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France | |
| Room | Session EPR122 / Screen B12 | |
| Date/Time | June 16, 2018, 13:30 - 14:15 CEST |
| #EPR1007 |
Double-blind argument for a synergistic therapeutic effect of a
fixed low-dose combination |
|
| Presenter: | Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France | |
| Room | Session EPR101 / Screen A1 | |
| Date/Time | June 16, 2018, 13:30 - 14:15 CEST |
International Congress on Neuromuscular Diseases (ICNMD)
July
6-10, 2018 in Vienna, Austria
Two Posters
| #545 | Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats. | |
| Authors | T. Prukop et al. | |
| Room | Mezzanine Floor Gallery and Foyers | |
| Date/Time | July 8, 2018, 5:15pm - 6:30pm CEST |
| #728 |
Baclofen, naltrexone and sorbitol all contribute to
PXT3003-induced myelination in CMT1A |
|
| Authors | N. Cholet et al. | |
| Room | Session Room 1 | |
| Date/Time | July 8, 2018, 5:15pm - 6:30pm CEST |
Innovations and State of the Art In Dementia Research meeting (ISADR)
July
16-18, 2081 in Valencia, Spain
Two Oral Communications
|
Cmax-based synergistic therapeutic effect on cognitive
disability in mild Alzheimer’s |
||
| Presenter: | Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France | |
| Date/Time | July 16, 2018, 11:35am - 11:55am CEST |
| A potential tri-therapy for Alzheimer’s disease. | ||
| Presenter: | Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France | |
| Date/Time | July 16, 2018, 12:55pm - 1:15pm CEST |
Peripheral Nerve Society (PNS) congress
July 22-25, 2018 in
Baltimore, US
One Oral Communication
|
Status of the Pivotal Phase III Study of PXT3003 for
Charcot-Marie-Tooth Type 1A disease |
||
| Presenter: | Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France | |
| Date/Time | July 23, 2018, 2.45pm - 3.00pm EST |
Four Posters
| #20 | Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats. | |
| Authors | R. Hajj et al. | |
| Session | Session 1 | |
| Date/Time | July 22, 2018 |
| #45 |
Status of the Pivotal Phase III Study of PXT3003 for
Charcot-Marie-Tooth Type 1A disease |
|
| Authors | R. Goedkoop et al. | |
| Session | Session 2 | |
| Date/Time | July 23, 2018 |
| #85 |
Synergy of baclofen, naltrexone and sorbitol (PXT3003) in
Charcot-Marie-Tooth Type 1A |
|
| Authors | J. Laffaire et al | |
| Session | Session 2 | |
| Date/Time | July 23, 2018 |
| #1 |
Baclofen, naltrexone and sorbitol all contribute to
PXT3003-induced myelination in CMT1A |
| Authors | R. Hajj et al. |
| Session | Session 3 |
| Date/Time | July 24, 2018 |
Alzheimer's Association International Conference (AAIC)
July
22-26, 2018 in Chicago, US
Two Posters
| #P1-061 |
Double-blind argument for a synergistic therapeutic effect of a
fixed low-dose combination |
|
| Authors | J-M Orgogozo et al | |
| Session | Session P1-01 / Hall F1 | |
| Date/Time | July 22, 2018, 9:30am - 4:15pm EST |
| #P3-042 |
PXT864 combination restores cognitive deficits of Alzheimer’s
mice, even in animals with |
|
| Authors | A. Brureau et al. | |
| Session | Session P3-02, Hall F1 | |
| Date/Time | July 24, 2018, 9:30am - 4:15pm EST |
If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to [email protected]
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan and
common neurodegenerative diseases that currently lack curative and/or
disease-modifying treatments. Pharnext has two lead products in clinical
development. PXT3003 is currently in an international Phase 3 trial for
the treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. The results of this
trial are expected in the second half of 2018. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext has developed
a new drug discovery paradigm based on big genomic data and artificial
intelligence: PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key advantages:
efficacy, safety and robust intellectual property. The Company was
founded by renowned scientists and entrepreneurs including Professor
Daniel Cohen, a pioneer in modern genomics and is supported by a
world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
code: FR0011191287).
For more information, visit http://www.pharnext.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180611005795/en/
